Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man.
Plasma concentrations of glucagon, insulin, glucose, and individual plasma amino acids were measured in normal nonobese and obese subjects before and after 3 days of dexamethasone treatment (2 mg/day) and in patients with Cushing's syndrome. The subjects were studied in the basal postabsorptive state and following the infusion of alanine (0.15 g/kg) or ingestion of a protein meal. In nonobese subjects dexamethasone treatment resulted in a 55% increment in basal glucagon levels and in a 60-100% increase in the maximal glucagon response to alanine infusion or protein ingestion. In obese subjects, basal glucagon rose by 110% following dexamethasone, while the response to alanine increased fourfold. In patients with Cushing's syndrome basal glucagon levels were 100% higher and the glucagon response to alanine infusion was 170% greater than in normal controls.Dexamethasone treatment in normal subjects resulted in a 40% rise in plasma alanine concentration which was directly proportional to the rise in basal glucagon. The remaining 14 amino acids were unchanged. In the patients with Cushing's syndrome alanine levels were 40% higher than in normal controls and were directly proportional to basal glucagon concentrations. No other plasma amino acids were significantly altered in the group with Cushing's syndrome. It is concluded that (a) glucocorticoids increase plasma glucagon concentration in the basal state and in response to protein ingestion or aminogenic stimulation; (b) this effect of glucocorticoids occurs in the face of obesity and persists in chronic hypercorticism; (c) hyperalaninemia is a characteristic of acute and chronic glucocorticoid excess, and may in turn contribute to steroid-induced hyperglucagonemia; and (d) increased alpha cell secretion may be a contributory factor in the gluconeogenic and diabetogenic effects of glucocorticoids.
D000328:Adult; D000409:Alanine / Q000008:administration & dosage / Q000494:pharmacology; D000596:Amino Acids / Q000097:blood*; D001786:Blood Glucose / Q000032:analysis; D003480:Cushing Syndrome / Q000503:physiopathology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004044:Dietary Proteins / Q000008:administration & dosage; D005215:Fasting; D005260:Female; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D005938:Glucocorticoids / Q000494:pharmacology*; D005951:Glucose Tolerance Test; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism
D000596:Amino Acids; D001786:Blood Glucose; D004044:Dietary Proteins; D005938:Glucocorticoids; D007328:Insulin; D003907:Dexamethasone; D005934:Glucagon; D000409:Alanine